Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke
The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptomatic intracranial hemorrhage compared to standard care.



















